Ponatinib -- Strategies About How Along with The Reason Why You Can Easily Reap Some Benefits Out Of

Brusamolino,5 A. Santoro,1. 1Hematology, Humanitas Cancer Center, Rozzano Milano, Italy,2Hematology, Niguarda Hospital, Milano, Italy, 3Medical Oncology, CRO, Aviano, Italy,4Biotecnologie Cellulari http://www.selleck.cn/products/AP24534.html Ematologia, Universita, Roma, Italy,5Hematology, San Matteo Hospital, Pavia, Italy, 6Hematology, Casa Sollievo della Sofferenza, SG Rotondo, Italy,7Hematology, Pescara, Pescara, Italy,8Hematology, Latina, Latina, Italy, 9Hematology, Torino Molinette, Torino, Italy,10Hematology, San Martino Hospital, Genova, Italy,11Hematology, Careggi Hospital, Firenze, Italy,12Hematology, S. Antonio e Biagio Hospital, Alessandria, Italy,13Medical Oncology, Centro Oncologico Medirraneo, Catania, Italy,14Medical Oncology, San Carlo Hospital, Milano, Italy,15Hematology, Spedali Civili, Brescia, Italy,16Hematology, Businco Hospital, Cagliari, Italy Introduction: Pts with R/R HL are treated with induction http://www.selleckchem.com/products/Rapamycin.html chemotherapy followed by ASCT. IGEV (ifosfamide, vinorelbine, gemcitabine) attainsboth highcomplete remission (CR) rate and mobilizing potential and itis the most widely used in this setting in Italy. We carried out a retrospective analysis in order to reassess the most common prognostic factors in a homogeneously treated pts population. Methods: We collected data of pts treated with IGEV and ASCT in Italy from 1997 to 2007. Pts were at least 18?year old and were scheduled to receive 2 to 4 pre-transplant IGEV courses. For each prognostic factor, the survival distribution was estimated http://www.selleckchem.com/products/jq1.html through Kaplan�CMeier method. Log-rank test was used to test differences between survival distributions in univariate analysis. Results: 330 patents are evaluable. Main clinical characteristics: median age 32; M/F 57%/43%; previous regimens 1 64%, > 2 36%; refractory/relapsed 51%/49%; B symptoms 15%, bulky 21%, extranodal 13%. Post-IGEV CR was obtained in 39% of cases evaluated with CT scan, and in 52% of 204 cases evaluated with PET. Overall, 269 pts proceeded to transplant after IGEV or further chemo. With a median follow-up of 57.7?months for the whole population, median PFS was 50,6?months and median OS was not reached. The following table reports factors influencing4-year outcome in univariate analysis: Abstract 142 Table 1. Characteristic PFS 4?years p-value OS 4?years p-value All 52.3 ? 73.3 ? Age 12/